Neurofibroma Pipeline Landscape Overview and Outlook, 2020 -

DUBLIN--()--The "Neurofibroma - Pipeline Insight, 2020" drug pipelines has been added to's offering.

Neurofibroma Pipeline Insight, 2020 outlays comprehensive insights of present clinical development scenario and growth prospects across the Neurofibroma market.

A detailed picture of the Neurofibroma pipeline landscape is provided, which includes the disease overview and Neurofibroma treatment guidelines. The assessment part of the report embraces in-depth Neurofibroma commercial assessment and clinical assessment of the Neurofibroma pipeline products from the pre-clinical developmental phase to the marketed phase.

In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Neurofibroma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

The report provides insights into:

  • All of the companies that are developing therapies for the treatment of Neurofibroma with aggregate therapies developed by each company for the same.
  • Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Neurofibroma treatment.
  • Neurofibroma key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Neurofibroma market.

Scope of the Report

  • The Neurofibroma report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Neurofibroma across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Neurofibroma therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Neurofibroma research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Neurofibroma.

Report Highlights

  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Neurofibroma.
  • In the coming years, the Neurofibroma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics that are working to assess challenges and seek opportunities that could influence Neurofibroma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • A detailed portfolio of major pharma players who are involved in fueling the Neurofibroma treatment market. Several potential therapies for Neurofibroma are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Neurofibroma market size in the coming years.
  • Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Neurofibroma) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Key Topics Covered

1. Report Introduction

2. Neurofibroma

2.1. Overview

2.2. History

2.3. Neurofibroma Symptoms

2.4. Causes

2.5. Pathophysiology

2.6. Neurofibroma Diagnosis

2.6.1. Diagnostic Guidelines

3. Neurofibroma Current Treatment Patterns

3.1. Neurofibroma Treatment Guidelines

4. Neurofibroma - Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Neurofibroma companies collaborations, Licensing, Acquisition - Deal Value Trends Assessment Summary

4.1.2. Neurofibroma Collaboration Deals Company-Company Collaborations (Licensing / Partnering) Analysis Company-University Collaborations (Licensing / Partnering) Analysis Neurofibroma Acquisition Analysis

5. Therapeutic Assessment

5.1. Clinical Assessment of Pipeline Drugs

5.1.1. Assessment by Phase of Development

5.1.2. Assessment by Product Type (Mono / Combination) Assessment by Stage and Product Type

5.1.3. Assessment by Route of Administration Assessment by Stage and Route of Administration

5.1.4. Assessment by Molecule Type Assessment by Stage and Molecule Type

5.1.5. Assessment by MOA Assessment by Stage and MOA

5.1.6. Assessment by Target Assessment by Stage and Target

6. Neurofibroma Late Stage Products (Phase-III)

7. Neurofibroma Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Neurofibroma Discontinued Products

13. Neurofibroma Product Profiles

13.1. Drug Name: Company

13.1.1. Product Description Product Overview Mechanism of action

13.1.2. Research and Development Clinical Studies

13.1.3. Product Development Activities Collaboration Agreements Acquisition Patent Detail

13.1.4. Tabulated Product Summary General Description Table

14. Neurofibroma Key Companies

15. Neurofibroma Key Products

16. Dormant and Discontinued Products

16.1. Dormant Products

16.1.1. Reasons for being dormant

16.2. Discontinued Products

16.2.1. Reasons for the discontinuation

17. Neurofibroma Unmet Needs

18. Neurofibroma Future Perspectives

19. Neurofibroma Analyst Review

Companies Mentioned

  • SpringWorks Therapeutics, Inc.
  • Region Skane
  • Novartis
  • Array BioPharma
  • AstraZeneca
  • Genentech, Inc.

For more information about this drug pipelines report visit

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900